Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 9/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29520942 | 1.00 | DGAT1 (0.47) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL14873045 | 0.84 | DGAT1 (0.49) | DGAT1FFAR1LPLLIPGCA1 | |
| SCHEMBL1180716 | 0.83 | DGAT1 (0.48) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL27088182 | 0.83 | DGAT1 (0.41) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL21721888 | 0.80 | DGAT1 (0.50) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL10249044 | 0.80 | DGAT1 (0.56) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL2486269 | 0.80 | DGAT1 (0.46) | DGAT1FFAR1LPLLIPGCA1 | |
| SCHEMBL27095110 | 0.80 | DGAT1 (0.36) | DGAT1FFAR1LPLLIPGAAK1 | |
| SCHEMBL19329278 | 0.79 | DGAT1 (0.48) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL25066062 | 0.78 | DGAT1 (0.46) | DGAT1FFAR1LPLLIPGAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11220509-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210230168-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210101904-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-04-08 | — | — | US | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-9925528-B2 | Catalyst-controlled aliphatic C—H oxidations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925528-B2 | Catalyst-controlled aliphatic C—H oxidations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925528-B2 | Catalyst-controlled aliphatic C—H oxidations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2017162611-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162611-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-28 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| WO-2015035412-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035412-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | DGAT1 2877/4885FFAR1 3582/4885LPL 3662/4885 |
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | HMOX1, SOD3, CYC1 | DGAT1 3385/4885FFAR1 3709/4885LPL 3054/4885 |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | DGAT1 4513/4885FFAR1 660/4885LPL 4375/4885 |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | DGAT1 2584/4885FFAR1 3892/4885LPL 3655/4885 |
| US-11220509-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | DGAT1 3239/4885FFAR1 3595/4885LPL 3061/4885 |
| US-20210101904-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | DGAT1 1231/4885FFAR1 3959/4885LPL 2258/4885 |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | DGAT1 4513/4885FFAR1 660/4885LPL 4375/4885 |
| US-20210032252-A1 | PRC2 Inhibitors | EZH2, BMI1, SUZ12 | DGAT1 1231/4885FFAR1 3959/4885LPL 2258/4885 |
| US-20210230168-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | DGAT1 1231/4885FFAR1 3959/4885LPL 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.